IDYA (IDEAYA Corp) שווי פירמה כולל

IDEAYA Biosciences (IDYA) relies on external partners (CROs and CMOs) to conduct all clinical trials. This asset-light model allows the company to focus on US-based R&D centers while outsourcing drug manufacturing to contract factories. The company has made a breakthrough in synthetic lethality, preparing inhibitors for melanoma therapy for release. The current enterprise value is 2432.74, which is confirmed by the price chart below illustrating valuation trends.

Enterprise value sums market capitalization and debt obligations, minus liquid assets, which determines the actual price for a full business acquisition. Analyzing the real business value of IDEAYA Biosciences (IDYA), an investor assesses the market value of developing precision oncology molecules, where a high valuation confirms the fundamental potential for a transition from general chemotherapy to high-precision genomic medicine.